Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q1 FY27 results · Apr–Jun 2026
Cohance Lifesciences reported revenue from operations of ₹422.26 crore (down 23.1% from Q1 FY26) and net loss of ₹45.19 crore for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 422.26 | 549.31 | −23.1% | 619.12 | −31.8% |
| Other income | 12.25 | 14.17 | −13.5% | (1.84) | Turned profit |
| Total income | 434.51 | 563.48 | −22.9% | 617.28 | −29.6% |
| Profit before tax | (42.87) | 62.76 | Turned loss | 19.91 | Turned loss |
| Net profit for the period | (45.19) | 46.40 | Turned loss | 8.31 | Turned loss |
| Attributable to shareholders of the company | (24.12) | 48.88 | Turned loss | 19.55 | Turned loss |
| EPS, basic (₹) | (0.63) | 1.28 | Turned loss | 0.51 | Turned loss |
| Net margin (%) | -10.7 | 8.4 | 1.3 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 359.89 | 483.58 | −25.6% | 567.55 | −36.6% |
| Other income | 12.16 | 13.10 | −7.2% | (0.79) | Turned profit |
| Total income | 372.05 | 496.68 | −25.1% | 566.76 | −34.4% |
| Profit before tax | 2.21 | 71.04 | −96.9% | 56.44 | −96.1% |
| Net profit for the period | 1.41 | 52.57 | −97.3% | 34.56 | −95.9% |
| EPS, basic (₹) | 0.04 | 1.38 | −97.1% | 0.90 | −95.6% |
| Net margin (%) | 0.4 | 10.9 | 6.1 |
Consolidated
- Filed with BSE
- 05 Aug 2026, 20:12 IST
- Board meeting
- 05 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 Aug 2026, 20:12 IST
- Board meeting
- 05 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE